Anthony P. West

This study shows a novel two-step mechanism for inducing broadly neutralizing HIV antibodies in macaques using a modified SHIV, informing vaccine design.

This paper identifies a potent, broad neutralizing antibody targeting a glycan-independent V3 epitope on HIV-1 Env, showing enhanced neutralization potency and resistance to escape mutations.

The paper identifies a new broadly neutralizing antibody, 04_A06, with high potency and breadth against HIV-1 strains, showing potential for prevention and therapy.

This paper designs and tests an HIV-1 vaccine candidate that targets three bNAb epitopes, showing it elicits combined immune responses in animal models.

This paper develops mosaic RBD-nanoparticles to induce cross-reactive anti-sarbecovirus antibodies in animals, demonstrating their effectiveness against SARS-CoV-2 variants and zoonotic viruses.

The paper identifies minimal somatic hypermutations required for CD4bs bNAb neutralization breadth and uses structural data to guide HIV-1 vaccine immunogen design.

The paper shows mosaic-8b nanoparticles induce broader cross-reactive antibodies than homotypic ones, even in pre-vaccinated animals, suggesting potential for improved vaccine design against emerging sarbecoviruses.

The paper detects and characterizes the SARS-CoV-2 lineage B.1.526 in New York, showing its rapid growth and potential impact on neutralization.

The paper classifies neutralizing antibodies against SARS-CoV-2 spike RBD based on structure, identifying binding modes and implications for vaccine and therapeutic strategies.

The paper analyzes HIV-1 broadly neutralizing antibodies to classify epitopes and identify potential vaccine candidates based on structural and immunological features.